These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28192473)

  • 1. Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status.
    Suda K; Rozeboom L; Yu H; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    PLoS One; 2017; 12(2):e0172209. PubMed ID: 28192473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
    Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
    Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
    Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
    Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromodomain and hedgehog pathway targets in small cell lung cancer.
    Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
    Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
    Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
    Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
    Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
    Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYCL1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected Small-Cell Lung Carcinoma.
    Qin J; Xie F; Li C; Han N; Lu H
    Pathol Oncol Res; 2021; 27():1609775. PubMed ID: 34257619
    [No Abstract]   [Full Text] [Related]  

  • 8. lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation.
    Tokgun O; Tokgun PE; Inci K; Akca H
    Anticancer Agents Med Chem; 2020; 20(17):2074-2081. PubMed ID: 32698750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myc protein expression correlates with MYC amplification in small-cell lung carcinoma.
    Hwang DH; Sun H; Rodig SJ; Hornick JL; Sholl LM
    Histopathology; 2015 Jul; 67(1):81-9. PubMed ID: 25407018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung Cancer.
    Plotnik JP; Zha Z; Feng W; Lee I; Riehm J; McClure RA; Sandoval S; Uziel T; Murphy E; Lu X; Lam LT
    Mol Cancer Res; 2024 Aug; 22(8):689-698. PubMed ID: 38747975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
    Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
    Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
    Hsu TY; Simon LM; Neill NJ; Marcotte R; Sayad A; Bland CS; Echeverria GV; Sun T; Kurley SJ; Tyagi S; Karlin KL; Dominguez-Vidaña R; Hartman JD; Renwick A; Scorsone K; Bernardi RJ; Skinner SO; Jain A; Orellana M; Lagisetti C; Golding I; Jung SY; Neilson JR; Zhang XH; Cooper TA; Webb TR; Neel BG; Shaw CA; Westbrook TF
    Nature; 2015 Sep; 525(7569):384-8. PubMed ID: 26331541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [DDP-sensitivity-related genes in 10 lung cancer cell lines].
    Li CH; Cai L; Chen XS; Meng QW; Sui GJ
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):418-21. PubMed ID: 19024514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
    Kashyap MK; Kumar D; Villa R; La Clair JJ; Benner C; Sasik R; Jones H; Ghia EM; Rassenti LZ; Kipps TJ; Burkart MD; Castro JE
    Haematologica; 2015 Jul; 100(7):945-54. PubMed ID: 25862704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer.
    Hamilton G; Stickler S; Rath B
    Curr Cancer Drug Targets; 2024; 24(9):930-940. PubMed ID: 38275056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 orchestrates the response to BI-2536 and its combination with alisertib in MYC-driven small cell lung cancer.
    Zhang J; Liu X; Hou P; Lv Y; Li G; Cao G; Wang H; Lin W
    Cell Death Dis; 2024 Jul; 15(7):551. PubMed ID: 39085197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer.
    Huang F; Huffman KE; Wang Z; Wang X; Li K; Cai F; Yang C; Cai L; Shih TS; Zacharias LG; Chung A; Yang Q; Chalishazar MD; Ireland AS; Stewart CA; Cargill K; Girard L; Liu Y; Ni M; Xu J; Wu X; Zhu H; Drapkin B; Byers LA; Oliver TG; Gazdar AF; Minna JD; DeBerardinis RJ
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33079728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
    Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
    BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
    Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
    Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.